drugset / Trial / NCT02171611

Bioavailability of Different Applications of Dabigatran in Healthy Volunteers

NCT02171611

Phase 1 Completed 30 enrolled Boehringer Ingelheim
RandomizedCrossoverOpen-labelTreatment

Summary

To determine the relative bioavailability of 150 mg of dabigatran etexilate as pellets on food and of 150 mg of dabigatran etexilate as powder resolved in reconstitution solution, both with 150 mg of dabigatran etexilate as capsule in healthy volunteers

Timeline

Start
2009-03
Primary completion
2009-05
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Dabigatran etexilate Unknown 150 mg Oral

Indications

No indication recorded.